{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:31:24Z","timestamp":1786509084368,"version":"build-2736575974"},"reference-count":90,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Endometrial and cervical cancers can recur from subclinical disease not evident on routine surveillance. This narrative review critically evaluates liquid biopsy for minimal residual disease (MRD) assessment and recurrence monitoring. Post-treatment human papillomavirus (HPV) circulating tumor DNA (ctDNA) in cervical cancer has the strongest disease-specific prospective evidence of clinical validity; persistent detection is strongly associated with recurrence, but moderate sensitivity and false-negative results do not support treatment de-escalation on negativity alone. With regard to endometrial cancer, perioperative ctDNA has prognostic support from an 11-study, 1298-patient meta-analysis and additional cohorts, although assay heterogeneity and limited independent replication constrain clinical readiness. Postoperative positivity generally shows stronger associations than preoperative detection. Cervicovaginal and urine DNA-methylation studies provide preliminary evidence for detecting established recurrence, especially local recurrence, but not prospective molecular lead time or clinical utility. Digital PCR, disease-specific fixed panels, tumor-informed assays, and error-corrected sequencing serve distinct settings; broad pan-cancer plasma profiling remains mainly an advanced-disease tool. Circulating tumor cells, extracellular vesicles, microRNAs, tumor-educated platelets, and fragmentomics remain exploratory. Liquid biopsy should remain an investigational adjunct until prospective trials show that acting on molecular findings improves outcomes.<\/jats:p>","DOI":"10.3390\/ijms27167155","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:10:24Z","timestamp":1786374624000},"page":"7155","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Liquid Biopsy for Minimal Residual Disease Assessment in Endometrial and Cervical Cancers: Molecular Rationale, Clinical Evidence, and Translational Barriers"],"prefix":"10.3390","volume":"27","author":[{"given":"Ludovica","family":"Pepe","sequence":"first","affiliation":[{"name":"Anatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age \u201cGaetano Barresi\u201d, University of Messina, 98125 Messina, Italy"},{"name":"PhD Program in Translational Molecular Medicine and Surgery, Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3478-9217","authenticated-orcid":false,"given":"Valeria","family":"Zuccal\u00e0","sequence":"additional","affiliation":[{"name":"Anatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age \u201cGaetano Barresi\u201d, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8530-2474","authenticated-orcid":false,"given":"Walter Giuseppe","family":"Giordano","sequence":"additional","affiliation":[{"name":"PhD Program in Translational Molecular Medicine and Surgery, Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordana","family":"Di Mauro","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1274-3514","authenticated-orcid":false,"given":"Vincenzo","family":"Cianci","sequence":"additional","affiliation":[{"name":"Section of Legal Medicine, Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mondello","sequence":"additional","affiliation":[{"name":"Section of Legal Medicine, Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9837-9148","authenticated-orcid":false,"given":"Massimiliano","family":"Berretta","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1132-1761","authenticated-orcid":false,"given":"Vincenzo","family":"Fiorentino","sequence":"additional","affiliation":[{"name":"Anatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age \u201cGaetano Barresi\u201d, University of Messina, 98125 Messina, Italy"},{"name":"PhD Program in Translational Molecular Medicine and Surgery, Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2878-3572","authenticated-orcid":false,"given":"Antonio","family":"Ieni","sequence":"additional","affiliation":[{"name":"Anatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age \u201cGaetano Barresi\u201d, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"World Health Organization (2026, July 30). Cervical Cancer. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cervical-cancer."},{"key":"ref_3","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","article-title":"Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease","volume":"11","author":"Moding","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ygyno.2025.11.014","article-title":"Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement","volume":"204","author":"Salani","year":"2026","journal-title":"Gynecol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer: Current status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"109682","DOI":"10.1016\/j.radonc.2023.109682","article-title":"ESGO\/ESTRO\/ESP Guidelines for the management of patients with cervical cancer\u2014Update 2023","volume":"184","author":"Cibula","year":"2023","journal-title":"Radiother. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.diii.2022.05.005","article-title":"Detection of parametrial invasion in women with uterine cervical cancer using diffusion tensor imaging at 1.5T MRI","volume":"103","author":"Perillo","year":"2022","journal-title":"Diagn. Interv. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"pkad040","DOI":"10.1093\/jncics\/pkad040","article-title":"Utility of ctDNA in predicting relapse in solid tumors after curative therapy: A meta-analysis","volume":"7","author":"Mittal","year":"2023","journal-title":"JNCI Cancer Spectr."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Pepe, L., Zuccal\u00e0, V., Giordano, W.G., Giuffr\u00e8, G., Martini, M., Cianci, V., Mondello, C., Berretta, M., Cianci, S., and Fiorentino, V. (2026). Circulating Tumor DNA in Ovarian Cancer: Emerging Roles in Early Detection, Risk Stratification, and Disease Monitoring. Cancers, 18.","DOI":"10.3390\/cancers18081312"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Shaw","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: Update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1007\/s00330-024-11094-8","article-title":"ESR Essentials: Staging and restaging with FDG-PET\/CT in oncology-practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging","volume":"35","author":"Ebner","year":"2025","journal-title":"Eur. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2023.12.025","article-title":"Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies","volume":"182","author":"Recio","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.23.00954","article-title":"Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer","volume":"42","author":"Han","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e70282","DOI":"10.1002\/cncr.70282","article-title":"Ultrasensitive next-generation sequencing-based detection of circulating human papillomavirus DNA for cervical cancer recurrence monitoring","volume":"132","author":"Stougaard","year":"2026","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"105161","DOI":"10.1016\/j.critrevonc.2026.105161","article-title":"Diagnostic and prognostic significance of circulating HPV cfDNA in cervical cancer: A systematic review and meta-analysis","volume":"220","author":"Parida","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-21-0625","article-title":"Circulating HPV DNA as a marker for early detection of relapse in patients with cervical cancer","volume":"27","author":"Jeannot","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1158\/1078-0432.CCR-24-2343","article-title":"Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Patients with Cervical Cancer Undergoing Definitive Chemoradiation","volume":"31","author":"Seo","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s11864-024-01180-w","article-title":"Circulating Tumor DNA (ctDNA) and Its Role in Gynecologic Malignancies","volume":"25","author":"Pomerantz","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Grabuschnig, S., Bronkhorst, A.J., Holdenrieder, S., Rosales Rodriguez, I., Schliep, K.P., Schwendenwein, D., Ungerer, V., and Sensen, C.W. (2020). Putative Origins of Cell-Free DNA in Humans: A Review of Active and Passive Nucleic Acid Release Mechanisms. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218062"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e2025052","DOI":"10.4084\/MJHID.2025.052","article-title":"Cuproptosis: A review on mechanisms, role in solid and hematological tumors, and association with viral infections","volume":"17","author":"Tralongo","year":"2025","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Underhill, H.R., Kitzman, J.O., Hellwig, S., Welker, N.C., Daza, R., Baker, D.N., Gligorich, K.M., Rostomily, R.C., Bronner, M.P., and Shendure, J. (2016). Fragment Length of Circulating Tumor DNA. PLoS Genet., 12.","DOI":"10.1371\/journal.pgen.1006162"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"eaat4921","DOI":"10.1126\/scitranslmed.aat4921","article-title":"Enhanced detection of circulating tumor DNA by fragment size analysis","volume":"10","author":"Mouliere","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"B\u00f8nl\u00f8kke, S., Stougaard, M., Sorensen, B.S., Booth, B.B., H\u00f8gdall, E., Nyvang, G.B., Lindegaard, J.C., Blaak\u00e6r, J., Bertelsen, J., and Fuglsang, K. (2022). The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients. Cells, 11.","DOI":"10.3390\/cells11142170"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.clinbiochem.2016.03.012","article-title":"Comparative analysis of circulating tumor DNA stability in K3EDTA, Streck, and CellSave blood collection tubes","volume":"49","author":"Kang","year":"2016","journal-title":"Clin. Biochem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41392-024-01938-6","article-title":"Circulating tumor cells: From new biological insights to clinical practice","volume":"9","author":"Gu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Rushton, A.J., Nteliopoulos, G., Shaw, J.A., and Coombes, R.C. (2021). A Review of Circulating Tumour Cell Enrichment Technologies. Cancers, 13.","DOI":"10.3390\/cancers13050970"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.trecan.2021.07.001","article-title":"Better together: Circulating tumor cell clustering in metastatic cancer","volume":"7","author":"Schuster","year":"2021","journal-title":"Trends Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e12416","DOI":"10.1002\/jev2.12416","article-title":"MISEV2023: An updated guide to EV research and applications","volume":"13","author":"Welsh","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"102543","DOI":"10.1016\/j.tranon.2025.102543","article-title":"Extracellular vesicles as biomarkers for endometrial cancer\u2014A systematic review","volume":"62","author":"Baxter","year":"2025","journal-title":"Transl. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ludwig, N., Whiteside, T.L., and Reichert, T.E. (2019). Challenges in Exosome Isolation and Analysis in Health and Disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194684"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ijc.34504","article-title":"DNA methylation testing for endometrial cancer detection in urine, cervicovaginal self-samples and cervical scrapes","volume":"153","author":"Wever","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cncy.22657","article-title":"DNA methylation analysis in urinary samples: A useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group","volume":"131","author":"Pierconti","year":"2023","journal-title":"Cancer Cytopathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"108.e19","DOI":"10.1016\/j.urolonc.2021.11.013","article-title":"The Bladder EpiCheck test and cytology in the follow-up of patients with non-muscle-invasive high-grade bladder carcinoma","volume":"40","author":"Pierconti","year":"2022","journal-title":"Urol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ijc.35143","article-title":"Recurrent cervical cancer detection using DNA methylation markers in self-collected samples from home","volume":"156","author":"Schaafsma","year":"2025","journal-title":"Int. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1002\/ijc.70358","article-title":"Detection of recurrent endometrial cancer via DNA methylation analysis of cervicovaginal self-samples and urine","volume":"158","author":"Nouwens","year":"2026","journal-title":"Int. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/jth.13720","article-title":"Platelet RNA as a circulating biomarker trove for cancer diagnostics","volume":"15","author":"Best","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"\u0141ukasiewicz, M., Pastuszak, K., \u0141api\u0144ska-Szumczyk, S., R\u00f3\u017ca\u0144ski, R., In \u2018t Veld, S.G.J.G., Bie\u0144kowski, M., Stokowy, T., Ratajska, M., Best, M.G., and W\u00fcrdinger, T. (2021). Diagnostic Accuracy of Liquid Biopsy in Endometrial Cancer. Cancers, 13.","DOI":"10.3390\/cancers13225731"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2025.12.008","article-title":"Prognostic value of perioperative circulating tumor DNA in endometrial cancer: Systematic review & meta-analysis","volume":"205","author":"Ahmed","year":"2026","journal-title":"Gynecol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ygyno.2025.03.002","article-title":"Prognostic value of assessing ctDNA in patients with endometrial carcinoma\u2014An international multicenter study","volume":"195","author":"Lindemann","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"111388","DOI":"10.1016\/j.ejso.2026.111388","article-title":"Prognostic value of perioperative circulating tumor DNA (ctDNA) in endometrial cancer with high-risk features: A prospective observational study","volume":"52","author":"Harris","year":"2026","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"102871","DOI":"10.1016\/j.tranon.2026.102871","article-title":"Perioperative ctDNA as a prognostic biomarker in endometrial cancer\u2014The CODEC study","volume":"71","author":"Delahunty","year":"2026","journal-title":"Transl. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"100816","DOI":"10.1016\/j.mam.2019.07.008","article-title":"Circulating tumor cell as the functional aspect of liquid biopsy to understand the metastatic cascade in solid cancer","volume":"72","year":"2020","journal-title":"Mol. Asp. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e2500286","DOI":"10.1200\/PO-25-00286","article-title":"Using Circulating Tumor DNA-Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer","volume":"9","author":"Ketch","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"102773","DOI":"10.1016\/j.ijgc.2025.102773","article-title":"DNA-junction-based personalized liquid biopsy assays could inform management of aggressive endometrial cancer","volume":"36","author":"Harris","year":"2026","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Marlin, R., Jean-Laurent, M., Joachim, C., Vallard, A., Pennont, S., Suez-Panama, V., Rose, M., Ulric-Gervaise, S., Lusbec, S., and Bera, O. (2026). Feasibility of TP53-Mutated ctDNA Monitoring in High-Grade Endometrial Cancer Using Routine NGS. Cancers, 18.","DOI":"10.3390\/cancers18071102"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.3802\/jgo.2025.36.e5","article-title":"Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas","volume":"36","author":"Jamieson","year":"2025","journal-title":"J. Gynecol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41698-025-01246-4","article-title":"Design and evaluation of a custom circulating tumour DNA assay to detect endometrial cancer recurrence","volume":"10","author":"Wadsley","year":"2026","journal-title":"npj Precis. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"104767","DOI":"10.1016\/j.ijgc.2026.104767","article-title":"Evaluating the utility of circulating cell-free DNA in the context of endometrial cancer: A systematic scoping review","volume":"36","author":"Macdonald","year":"2026","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Lockwood, C.M., Messersmith, H.J., Kim, A.S., Rajagopal, P.S., Swami, U., Xian, R., Aisner, D., Arcila, M.E., Kurttila, F., and Lovly, C.M. (2026). Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline. JCO Oncol. Pract., OP-26-00311.","DOI":"10.1200\/OP-26-00311"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1021\/ac202028g","article-title":"High-throughput droplet digital PCR system for absolute quantitation of DNA copy number","volume":"83","author":"Hindson","year":"2011","journal-title":"Anal. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/nmeth.2633","article-title":"Absolute quantification by droplet digital PCR versus analog real-time PCR","volume":"10","author":"Hindson","year":"2013","journal-title":"Nat. Methods"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/s41587-021-00857-z","article-title":"SEQC2 Oncopanel Sequencing Working Group. Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology","volume":"39","author":"Deveson","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40291-021-00559-x","article-title":"Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors","volume":"25","author":"Chen","year":"2021","journal-title":"Mol. Diagn. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jmoldx.2023.11.007","article-title":"Comparing the Diagnostic Performance of Quantitative PCR, Digital Droplet PCR, and Next-Generation Sequencing Liquid Biopsies for Human Papillomavirus-Associated Cancers","volume":"26","author":"Naegele","year":"2024","journal-title":"J. Mol. Diagn."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41698-026-01348-7","article-title":"The clinical application value of dynamic monitoring of HPV ctDNA in concurrent chemoradiotherapy for locally advanced cervical cancer","volume":"10","author":"Zhang","year":"2026","journal-title":"npj Precis. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41698-026-01424-y","article-title":"Nanoplate based digital PCR assay for effective quantification of plasma HPV circulating tumor DNA","volume":"10","author":"Parida","year":"2026","journal-title":"npj Precis. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1158\/1078-0432.CCR-19-2384","article-title":"HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA","volume":"27","author":"Leung","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Santoro, A., Angelico, G., Travaglino, A., Inzani, F., Arciuolo, D., Valente, M., D\u2019Alessandris, N., Scaglione, G., Fiorentino, V., and Raffone, A. (2021). New pathological and clinical insights in endometrial cancer in view of the updated ESGO\/ESTRO\/ESP guidelines. Cancers, 13.","DOI":"10.3390\/cancers13112623"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Pizzimenti, C., Fiorentino, V., Ruggeri, C., Franchina, M., Ercoli, A., Tuccari, G., and Ieni, A. (2024). Autophagy involvement in non-neoplastic and neoplastic endometrial pathology: The state of the art with a focus on carcinoma. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252212118"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1159\/000508225","article-title":"The many faces of endometriosis-related neoplasms in the same patient: A brief report","volume":"85","author":"Santoro","year":"2020","journal-title":"Gynecol. Obstet. Investig."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Pizzimenti, C., Fiorentino, V., Pepe, L., Franchina, M., Ruggeri, C., Ercoli, A., Ciappina, G., Berretta, M., Tuccari, G., and Ieni, A. (2025). Predictive biomarkers for immunotherapy in endometrial carcinoma. Cancers, 17.","DOI":"10.3390\/cancers17152420"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Perez, M., Carvajal, L.L., Wong, A., Poppiti, R., Ruiz-Cordero, R., Castellano-S\u00e1nchez, A.A., and Bahmad, H.F. (2025). Beyond the Microscope: Integrating Liquid Biopsies into the Molecular Pathology Era of Endometrial Cancer. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26167987"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13046-024-03158-w","article-title":"Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: Towards the clinical application","volume":"43","author":"Vilar","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41379-018-0158-8","article-title":"Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: Identification of plasma-based, tumor-associated mutations in early stage patients","volume":"32","author":"Bolivar","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Moss, E.L., Gorsia, D.N., Collins, A., Sandhu, P., Foreman, N., Gore, A., Wood, J., Kent, C., Silcock, L., and Guttery, D.S. (2020). Utility of Circulating Tumor DNA for Detection and Monitoring of Endometrial Cancer Recurrence and Progression. Cancers, 12.","DOI":"10.1101\/2020.03.04.20030908"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e70463","DOI":"10.1111\/cts.70463","article-title":"Lexicon for Clonal Hematopoiesis in Liquid Biopsy","volume":"19","author":"Tell","year":"2026","journal-title":"Clin. Transl. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Nair, N., Camacho-Vanegas, O., Rykunov, D., Dashkoff, M., Camacho, S.C., Schumacher, C.A., Irish, J.C., Harkins, T.T., Freeman, E., and Garcia, I. (2016). Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002206"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1038\/s41416-023-02233-x","article-title":"Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse","volume":"128","author":"Mittelstadt","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1136\/ijgc-2020-001710","article-title":"Standard ultrastaging compared to one-step nucleic acid amplification (OSNA) for the detection of sentinel lymph node metastases in early stage cervical cancer","volume":"30","author":"Santoro","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): A randomised, double-blind, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_76","unstructured":"U.S. Food and Drug Administration (2026, July 30). FDA Approves Pembrolizumab with Chemoradiotherapy for FIGO 2014 Stage III\u2013IVA Cervical Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-chemoradiotherapy-figo-2014-stage-iii-iva-cervical-cancer."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Li, Y., Deng, J., Liu, Y., and Yu, S. (2025). HPV infection and the immune microenvironment in cervical cancer. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1645019"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.annonc.2025.05.533","article-title":"Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: Phase III CALLA trial analyses","volume":"36","author":"Mayadev","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_79","unstructured":"ClinicalTrials.gov (2026, August 01). Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer (NCT05531981), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05531981."},{"key":"ref_80","unstructured":"ClinicalTrials.gov (2026, August 01). CtDNA-Guided First-Line Immuno-De-Escalation Therapy for Stage IVB and Recurrent Cervical Cancer (NCT06878196), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06878196."},{"key":"ref_81","unstructured":"ClinicalTrials.gov (2026, August 01). CtDNA Testing to Inform Standard-of-Care Treatment Decisions in People with Endometrial Cancer (NCT07270666), Available online: https:\/\/clinicaltrials.gov\/study\/NCT07270666."},{"key":"ref_82","unstructured":"ClinicalTrials.gov (2026, August 01). Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation with Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer (NCT07061977), Available online: https:\/\/clinicaltrials.gov\/study\/NCT07061977."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Ciulla, S., Celli, V., Aiello, A.A., Gigli, S., Ninkova, R., Miceli, V., Ercolani, G., Dolciami, M., Ricci, P., and Palaia, I. (2022). Post treatment imaging in patients with local advanced cervical carcinoma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1003930"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2967\/jnumed.118.222893","article-title":"Introduction to Radiomics","volume":"61","author":"Mayerhoefer","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s13244-018-0657-7","article-title":"Radiomics and liquid biopsy in oncology: The holons of systems medicine","volume":"9","author":"Neri","year":"2018","journal-title":"Insights Imaging"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Pereira, E., Camacho-Vanegas, O., Anand, S., Sebra, R., Camacho, S.C., Garnar-Wortzel, L., Nair, N., Moshier, E., Wooten, M., and Uzilov, A. (2015). Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0145754"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41467-020-14310-3","article-title":"White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer","volume":"11","author":"Leal","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"100301","DOI":"10.1016\/j.jlb.2025.100301","article-title":"International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors","volume":"8","author":"Fusco","year":"2025","journal-title":"J. Liq. Biopsy"},{"key":"ref_90","unstructured":"U.S. Food and Drug Administration (2026, July 30). FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-atezolizumab-adjuvant-treatment-muscle-invasive-bladder-cancer-patients-molecular."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7155\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:16:00Z","timestamp":1786508160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":90,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27167155"],"URL":"https:\/\/doi.org\/10.3390\/ijms27167155","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]}}}